Biogen Sheds $5 Billion of Value as Drug Challenge Vexes Street

(Bloomberg) -- Biogen Inc. shares just posted their biggest one-day plunge since late July as investors weigh the intellectual property risks to the company’s top-selling drug Tecfidera.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.